CN106932371A - 一种细胞内谷胱甘肽的荧光成像方法 - Google Patents
一种细胞内谷胱甘肽的荧光成像方法 Download PDFInfo
- Publication number
- CN106932371A CN106932371A CN201710139629.8A CN201710139629A CN106932371A CN 106932371 A CN106932371 A CN 106932371A CN 201710139629 A CN201710139629 A CN 201710139629A CN 106932371 A CN106932371 A CN 106932371A
- Authority
- CN
- China
- Prior art keywords
- fluorescence imaging
- imaging method
- inside cell
- glutathion inside
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 144
- 229960003180 glutathione Drugs 0.000 title claims abstract description 79
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000000799 fluorescence microscopy Methods 0.000 title claims abstract description 30
- 235000003969 glutathione Nutrition 0.000 title claims abstract description 25
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000010931 gold Substances 0.000 claims abstract description 30
- 229910052737 gold Inorganic materials 0.000 claims abstract description 30
- 239000000523 sample Substances 0.000 claims abstract description 26
- 230000003287 optical effect Effects 0.000 claims abstract description 25
- 239000007850 fluorescent dye Substances 0.000 claims abstract description 13
- 238000013270 controlled release Methods 0.000 claims abstract description 12
- 108010024636 Glutathione Proteins 0.000 claims abstract description 11
- 238000003384 imaging method Methods 0.000 claims abstract description 3
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 17
- 229960003067 cystine Drugs 0.000 claims description 17
- 230000010355 oscillation Effects 0.000 claims description 6
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 claims description 6
- IOUNGFDUDUBFGX-UHFFFAOYSA-N n-(2-chlorophenyl)-2-[4-(2,4-dichlorophenyl)thiadiazol-5-yl]sulfanylacetamide Chemical compound ClC1=CC(Cl)=CC=C1C1=C(SCC(=O)NC=2C(=CC=CC=2)Cl)SN=N1 IOUNGFDUDUBFGX-UHFFFAOYSA-N 0.000 claims description 5
- 229940043267 rhodamine b Drugs 0.000 claims description 5
- NJSSICCENMLTKO-HRCBOCMUSA-N [(1r,2s,4r,5r)-3-hydroxy-4-(4-methylphenyl)sulfonyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)O[C@H]1C(O)[C@@H](OS(=O)(=O)C=2C=CC(C)=CC=2)[C@@H]2OC[C@H]1O2 NJSSICCENMLTKO-HRCBOCMUSA-N 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 239000000243 solution Substances 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 235000009508 confectionery Nutrition 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 230000009881 electrostatic interaction Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 abstract description 23
- 238000005516 engineering process Methods 0.000 abstract description 20
- 210000004027 cell Anatomy 0.000 abstract description 18
- 230000008901 benefit Effects 0.000 abstract description 9
- 238000013461 design Methods 0.000 abstract description 5
- 238000012544 monitoring process Methods 0.000 abstract description 5
- 230000004044 response Effects 0.000 abstract description 5
- 239000006185 dispersion Substances 0.000 abstract description 4
- 239000012528 membrane Substances 0.000 abstract description 4
- 230000035699 permeability Effects 0.000 abstract description 4
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 238000012377 drug delivery Methods 0.000 abstract 1
- 238000002626 targeted therapy Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 description 14
- 210000001519 tissue Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000008512 biological response Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000002539 nanocarrier Substances 0.000 description 3
- 231100001083 no cytotoxicity Toxicity 0.000 description 3
- -1 sulfhydryl compound Chemical class 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010053070 Glutathione Disulfide Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 241000218636 Thuja Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000002091 nanocage Substances 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710139629.8A CN106932371B (zh) | 2017-03-09 | 2017-03-09 | 一种细胞内谷胱甘肽的荧光成像方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710139629.8A CN106932371B (zh) | 2017-03-09 | 2017-03-09 | 一种细胞内谷胱甘肽的荧光成像方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106932371A true CN106932371A (zh) | 2017-07-07 |
CN106932371B CN106932371B (zh) | 2020-03-10 |
Family
ID=59433715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710139629.8A Active CN106932371B (zh) | 2017-03-09 | 2017-03-09 | 一种细胞内谷胱甘肽的荧光成像方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106932371B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110823848A (zh) * | 2018-08-13 | 2020-02-21 | 青岛科技大学 | 一种细胞内Ag+的荧光成像方法 |
CN112111552A (zh) * | 2020-08-05 | 2020-12-22 | 青岛科技大学 | 一种肿瘤细胞的荧光成像方法 |
CN113252621A (zh) * | 2020-02-12 | 2021-08-13 | 青岛科技大学 | 一种细胞内Hg2+和Ag+的同时荧光成像方法 |
CN113372904A (zh) * | 2021-06-08 | 2021-09-10 | 青岛科技大学 | 一种用于肿瘤成像和靶向协同治疗的谷胱甘肽响应纳米探针及其构建方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104931467A (zh) * | 2015-02-28 | 2015-09-23 | 青岛科技大学 | 一种细胞内atp的荧光成像方法 |
CN106093158A (zh) * | 2016-05-07 | 2016-11-09 | 上海大学 | 谷胱甘肽检测用生物传感器、其制备方法及其检测方法 |
-
2017
- 2017-03-09 CN CN201710139629.8A patent/CN106932371B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104931467A (zh) * | 2015-02-28 | 2015-09-23 | 青岛科技大学 | 一种细胞内atp的荧光成像方法 |
CN106093158A (zh) * | 2016-05-07 | 2016-11-09 | 上海大学 | 谷胱甘肽检测用生物传感器、其制备方法及其检测方法 |
Non-Patent Citations (1)
Title |
---|
徐升豪 等: "荧光金纳米簇的合成及其传感成像应用最新进展", 《青岛科技大学学报(自然科学版)》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110823848A (zh) * | 2018-08-13 | 2020-02-21 | 青岛科技大学 | 一种细胞内Ag+的荧光成像方法 |
CN110823848B (zh) * | 2018-08-13 | 2022-03-11 | 青岛科技大学 | 一种细胞内Ag+的荧光成像方法 |
CN113252621A (zh) * | 2020-02-12 | 2021-08-13 | 青岛科技大学 | 一种细胞内Hg2+和Ag+的同时荧光成像方法 |
CN112111552A (zh) * | 2020-08-05 | 2020-12-22 | 青岛科技大学 | 一种肿瘤细胞的荧光成像方法 |
CN113372904A (zh) * | 2021-06-08 | 2021-09-10 | 青岛科技大学 | 一种用于肿瘤成像和靶向协同治疗的谷胱甘肽响应纳米探针及其构建方法 |
Also Published As
Publication number | Publication date |
---|---|
CN106932371B (zh) | 2020-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Biomimetic preparation and dual-color bioimaging of fluorescent silicon nanoparticles | |
Huefner et al. | Characterization and visualization of vesicles in the endo-lysosomal pathway with surface-enhanced Raman spectroscopy and chemometrics | |
Martinez et al. | Detection of apoptosis: A review of conventional and novel techniques | |
CN106908429A (zh) | 一种检测谷胱甘肽的方法 | |
Faklaris et al. | Photoluminescent diamond nanoparticles for cell labeling: study of the uptake mechanism in mammalian cells | |
CN106932371A (zh) | 一种细胞内谷胱甘肽的荧光成像方法 | |
Dif et al. | Small and stable peptidic PEGylated quantum dots to target polyhistidine-tagged proteins with controlled stoichiometry | |
Fabris | Gold nanostars in biology and medicine: understanding physicochemical properties to broaden applicability | |
Wang et al. | Biocompatible fluorescent supramolecular nanofibrous hydrogel for long-term cell tracking and tumor imaging applications | |
Li et al. | A visible and near-infrared dual-fluorescent probe for discrimination between Cys/Hcy and GSH and its application in bioimaging | |
CN104220438A (zh) | 用于检测过氧亚硝酸盐的二芳基胺-基荧光探针 | |
Sharmin et al. | Fluorescent nanodiamonds for detecting free-radical generation in real time during shear stress in human umbilical vein endothelial cells | |
El-Sadik et al. | Nanoparticle-labeled stem cells: a novel therapeutic vehicle | |
CN105784666B (zh) | 一种纳米荧光生物传感器及其制备方法和应用 | |
Feng et al. | In vivo and in situ real-time fluorescence imaging of peripheral nerves in the NIR-II window | |
CN106404726A (zh) | 一种基于双链dna保护的荧光探针及在制备检测恶性疟原虫乳酸脱氢酶药物中的应用 | |
Dong et al. | Three-dimensional photonic nitrocellulose for minimally invasive detection of biomarker in tumor interstitial fluid | |
Nonaka et al. | Revisiting PFA-mediated tissue fixation chemistry: FixEL enables trapping of small molecules in the brain to visualize their distribution changes | |
Sammi et al. | Nano‐bio‐engineered silk matrix based devices for molecular bioanalysis | |
CN111999504B (zh) | 一种粘蛋白1及其唾液酸糖基的双重荧光成像方法及应用 | |
Jiang et al. | Sensitive and selective SERS probe for detecting the activity of γ-glutamyl transpeptidase in serum | |
Thompson et al. | Sensor technology in neuroscience | |
Ding et al. | Screening of HER2 overexpressed breast cancer subtype in vivo by the validation of high-performance, long-term, and noninvasive fluorescence tracer | |
JPWO2013039112A1 (ja) | 二次元培養細胞を三次元培養又は生体内と同様に活性化する方法及びその利用 | |
CN106802294A (zh) | 一种基于可控释放技术的谷胱甘肽荧光传感器及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230626 Address after: 230000 floor 1, building 2, phase I, e-commerce Park, Jinggang Road, Shushan Economic Development Zone, Hefei City, Anhui Province Patentee after: Dragon totem Technology (Hefei) Co.,Ltd. Address before: 266000 Laoshan campus, Songling Road, Laoshan District, Qingdao, Shandong, China, 99 Patentee before: QINGDAO University OF SCIENCE AND TECHNOLOGY Effective date of registration: 20230626 Address after: Room 802, Unit 3, No. 1, Huifeng Road, Guancheng Subdistrict, Dongguan, Guangdong 523000 Patentee after: Guangdong Hanji Tiancheng Gene Technology Co.,Ltd. Address before: 230000 floor 1, building 2, phase I, e-commerce Park, Jinggang Road, Shushan Economic Development Zone, Hefei City, Anhui Province Patentee before: Dragon totem Technology (Hefei) Co.,Ltd. |
|
TR01 | Transfer of patent right |